Myriad Genetics Engages With UnitedHealthcare on Access to GeneSight Test Following Policy Update
Myriad Genetics Engages With UnitedHealthcare on Access to GeneSight Test Following Policy Update
The GeneSight test helps inform clinicians about how a patient's genes may affect their response to over 60 psychiatric medications.Myriad Genetics updates on discussions with UnitedHealthcare regarding access to GeneSight test following policy changes effective January 2025.
萬基遺傳就與聯合健康保險公司（UnitedHealthcare）關於2025年1月生效的政策變更後對GeneSight測試獲取的討論進行了更新。
Quiver AI Summary
Quiver AI 概要
Myriad Genetics, Inc. has provided an update on its communication with UnitedHealthcare (UHC) regarding UHC's new medical policy, published on November 1, 2024, which restricts access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, effective January 1, 2025. Myriad is actively discussing the clinical evidence supporting GeneSight with UHC and has requested continued access to the test for UHC enrollees, emphasizing its utility in primary care for prescribing antidepressants. The company, led by CEO Paul J. Diaz, expresses condolences following the passing of UHC's CEO and remains committed to engaging in discussions, potentially extending into early 2025, while affirming confidence in GeneSight's clinical validity. Myriad estimates the financial impact of UHC's policy on its operations as it continues to provide genetic testing aimed at improving patient care.
萬基遺傳公司就其與聯合健康保險公司（UHC）之間的溝通進行了更新，UHC的新醫療政策於2024年11月1日發佈，該政策限制對多基因面板藥物基因組測試的獲取，包括萬基的GeneSight測試，自2025年1月1日起生效。萬基正在與UHC積極討論支持GeneSight的臨牀證據，並請求對UHC參保者繼續提供該測試的獲取，強調其在初級護理中對開處方抗抑鬱藥物的實用性。該公司由首席執行官保羅·J·迪亞斯領導，在UHC首席執行官去世後表示哀悼，並保持參與討論的承諾，這些討論可能延續到2025年初，同時重申對GeneSight臨牀有效性的信心。萬基估計UHC政策對其運營的財務影響，同時繼續提供旨在改善患者護理的基因檢測。
Potential Positives
潛在的積極因素
- Myriad Genetics is actively engaging in constructive dialogue with UnitedHealthcare to advocate for continued access to its GeneSight test in light of recent policy changes, indicating a proactive approach to partnership and patient access.
- The company reaffirms its confidence in the clinical validity and utility of the GeneSight test, supported by peer-reviewed research studies, which strengthens its position in the market for pharmacogenomic testing.
- Myriad's commitment to addressing concerns and presenting additional clinical data to UNH demonstrates its dedication to evidence-based practices and improving patient care in mental health treatment.
- The press release highlights the widespread use of the GeneSight test, with tens of thousands of clinicians having ordered it for nearly three million patients, showcasing its established presence and acceptance in the healthcare community.
- 萬基遺傳公司正在積極與聯合健康保險公司進行建設性對話，以倡導在近期政策變更的背景下繼續獲取其GeneSight測試，這表明其積極的合作與患者獲取的方式。
- 該公司重申對GeneSight測試的臨牀有效性和實用性的信心，這得到了經過同行評審的研究支持，進一步加強了其在藥物基因組測試市場中的地位。
- 萬基對回應關切和向UHC提供額外臨牀數據的承諾展示了其對基於證據的實踐的奉獻，並致力於改善心理健康治療中的患者護理。
- 新聞稿強調了GeneSight測試的廣泛使用，成千上萬的臨牀醫生已爲近三百萬名患者下單，展示了其在醫療社區中的已建立的存在和認可。
Potential Negatives
潛在負面因素
- The updated medical policy from UnitedHealthcare restricts access to Myriad's GeneSight test, potentially resulting in significant financial impact as estimated by the company.
- Myriad has not yet secured continued access for UHC enrollees to the GeneSight test, indicating uncertainties in patient access and company revenue.
- The press release comes in the context of the death of UnitedHealthcare's CEO, which could complicate discussions and negotiations moving forward.
- 來自健保的更新醫療政策限制了對萬基遺傳的GeneSight測試的訪問，這可能導致公司預計的重大財務影響。
- 萬基遺傳尚未爲UHC投保人確保持續進入GeneSight測試，這表明患者訪問和公司營業收入存在不確定性。
- 該新聞稿是在健保首席執行官去世的背景下發佈的，這可能會使未來的討論和談判變得複雜。
FAQ
常見問題
What recent policy change was announced by UnitedHealthcare?
健保最近公佈了哪些政策變更？
UnitedHealthcare announced an updated medical policy restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, effective January 1, 2025.
健保宣佈了一項更新的醫療政策，限制對多基因面板藥物基因組學測試的訪問，包括萬基遺傳的GeneSight測試，自2025年1月1日起生效。
What is the GeneSight test used for?
GeneSight測試用於什麼？
The GeneSight test helps inform clinicians about how a patient's genes may affect their response to over 60 psychiatric medications.
GeneSight測試有助於告知臨牀醫生患者的基因如何影響他們對超過60種精神藥物的反應。
What steps is Myriad Genetics taking in response to UnitedHealthcare's new policy?
萬基遺傳針對UnitedHealthcare新政策採取了哪些措施？
Myriad is engaging in dialogue with UnitedHealthcare, presenting additional clinical data to support continued access to the GeneSight test.
萬基遺傳正在與UnitedHealthcare進行對話，提供額外的臨牀數據以支持持續獲取GeneSight測試。
How has Myriad Genetics expressed condolences to UnitedHealthcare?
萬基遺傳是如何對UnitedHealthcare表達哀悼的？
Myriad Genetics expressed condolences following the tragic death of UnitedHealthcare CEO Brian Thompson on December 4, 2024.
萬基遺傳在2024年12月4日對UnitedHealthcare首席執行官布萊恩·湯普森的悲慘去世表示哀悼。
Where can I find more information about Myriad Genetics and GeneSight?
我在哪裏可以找到更多關於萬基遺傳和GeneSight的信息？
More information about Myriad Genetics and GeneSight can be found on their respective websites: and GeneSight.com.
關於萬基遺傳和GeneSight的更多信息可以在它們各自的網站上找到：和GeneSight.com。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免責聲明：這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發佈。
$MYGN Insider Trading Activity
$MYGN 內部交易活動
$MYGN insiders have traded $MYGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
$MYGN 內部人員在過去 6 個月內在公開市場交易了 7 次 $MYGN 股票。其中 0 次爲購買，7 次爲銷售。
Here's a breakdown of recent trading of $MYGN stock by insiders over the last 6 months:
以下是過去 6 個月內內部人員對 $MYGN 股票的最近交易情況：
- PAUL J DIAZ (President and CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 30,000 shares.
- DALE MUZZEY (Chief Scientific Officer) sold 2,100 shares.
- HEINRICH DREISMANN sold 10,000 shares.
- COLLEEN F REITAN sold 46,012 shares.
- MARGARET ANCONA (SVP, Chief of Staff) sold 11,538 shares.
- RASHMI KUMAR sold 7,500 shares.
- 保羅·J·迪亞茲（總裁兼首席執行官）交易了2次。他們沒有購買，出售了30,000股。
- 戴爾·穆澤（首席科學官）出售了2,100股。
- 海因裏希·德雷斯曼出售了10,000股。
- 科琳·F·瑞坦出售了46,012股。
- 瑪格麗特·安科納（高級副總裁，首席幕僚）出售了11,538股。
- 拉什米·庫馬爾出售了 7,500 股股票。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟蹤內部交易，請查看Quiver Quantitative的內部交易儀表。
$MYGN Hedge Fund Activity
$MYGN對沖基金活動
We have seen 131 institutional investors add shares of $MYGN stock to their portfolio, and 106 decrease their positions in their most recent quarter.
我們看到131家機構投資者在最近一個季度增加了$MYGN股票的持倉，106家減少了持倉。
Here are some of the largest recent moves:
以下是最近的一些重大變動：
- GLENVIEW CAPITAL MANAGEMENT, LLC removed 2,486,902 shares (-66.3%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 1,695,989 shares (-96.1%) from their portfolio in Q3 2024
- CAMBER CAPITAL MANAGEMENT LP removed 1,550,000 shares (-28.2%) from their portfolio in Q3 2024
- WELLINGTON MANAGEMENT GROUP LLP removed 1,545,842 shares (-18.7%) from their portfolio in Q3 2024
- LOOMIS SAYLES & CO L P added 1,326,497 shares (+153.7%) to their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 777,499 shares (+17.7%) to their portfolio in Q3 2024
- MORGAN STANLEY removed 491,650 shares (-35.8%) from their portfolio in Q3 2024
- GLENVIEW CAPITAL MANAGEMENT, LLC在2024年第三季度從其投資組合中剔除了2,486,902股（-66.3%）。
- CITADEL ADVISORS LLC在2024年第三季度從其投資組合中剔除了1,695,989股（-96.1%）。
- CAMBER CAPITAL MANAGEMENT LP在2024年第三季度從其投資組合中剔除了1,550,000股（-28.2%）。
- 韋靈頓管理集團在2024年第三季度從其投資組合中移除了1,545,842股(-18.7%)
- 盎格魯-摩根利薩公司在2024年第三季度向其投資組合中新增了1,326,497股(+153.7%)
- 千禧管理公司在2024年第三季度向其投資組合中新增了777,499股(+17.7%)
- 摩根士丹利在2024年第三季度從其投資組合中移除了491,650股(-35.8%)
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要跟蹤對沖基金的股票投資組合，請查看Quiver Quantitative的機構持有情況儀表。
Full Release
完整發佈
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) --
Myriad Genetics, Inc
. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealthcare (UNH) following the Nov 1, 2024 publication of its updated medical policy restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025.
鹽湖城，2024年12月10日（全球新聞網）--
萬基遺傳公司
. (納斯達克: 萬基遺傳)，在遺傳檢測和精準醫療領域的領導者，今天更新了與聯合醫療（UNH）之間的溝通情況，關於2024年11月1日發佈的更新醫療政策，該政策限制在其商業和個人交易所福利計劃下，訪問多個基因面板藥物基因組檢測，包括萬基的GeneSight檢測，政策將於2025年1月1日起生效。
Since the announcement, Myriad has actively engaged in constructive dialogue with UNH regarding the clinical evidence supporting Myriad's proprietary and clinically differentiated mental health medication test, GeneSight, including presenting additional clinical data to UnitedHealthcare for its further review and consideration. Myriad has requested that UHC enrollees continue to have access to the test in 2025, especially in the primary care setting where a significant majority of antidepressants are prescribed
1
.
自公告以來，萬基積極與聯合醫療（UNH）進行建設性對話，討論支持萬基專有及臨牀差異化的心理健康藥物檢測GeneSight的臨牀證據，包括向聯合醫療提供更多臨牀數據以供進一步審查和考慮。萬基已請求UHC參保者在2025年繼續可以使用該檢測，特別是在抗抑鬱藥物主要開處方的初級護理環境中。
1
.
"Following the tragic death of UnitedHealthcare CEO Brian Thompson on December 4th, we extend our deepest condolences to Brian's family and all employees of UnitedHealthcare. Soon, at the appropriate time, we plan to continue our dialogue with UNH and other key stakeholders," said Paul J. Diaz, President and CEO, Myriad Genetics. "We desire resolution ahead of year-end, but discussions may extend into early 2025. We remain steadfast in our confidence in the clinical validity and utility of GeneSight, which we believe is supported by clinical evidence, including peer-reviewed research studies."
「在聯合健康保險首席執行官布萊恩·湯普森於12月4日不幸去世後，我們向布萊恩的家人及所有聯合健康保險的員工緻以最深切的慰問。」 萬基遺傳的總裁兼首席執行官保羅·J·迪亞茲說：「我們希望在年末之前達成解決方案，但討論可能延續到2025年初。我們始終堅定對GeneSight的臨牀有效性和實用性的信心，我們相信這些都得到了臨牀證據的支持，包括同行評審的研究。」
During Myriad's third quarter earnings call held on November 6, 2024, the company provided an estimate of the 2024 financial impact of UNH's updated medical policy. While Myriad continues to engage with UNH, the company reaffirms this estimate.
在萬基於2024年11月6日召開的第三季度業績發佈會中，該公司提供了UNH更新醫療政策對2024年財務影響的初步估算。儘管萬基繼續與UNH溝通，但該公司重申了這一估算。
About the GeneSight
Psychotropic Test
The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for more than 60 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patient's genes may impact how they metabolize and/or respond to certain psychiatric medications. Tens of thousands of clinicians have ordered the GeneSight test for almost three million patients in order to receive genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. The clinical validity, clinical utility and economic utility of the GeneSight test have been evaluated in multiple peer-reviewed publications. Learn more at
GeneSight.com
.
關於GeneSight
精神藥理學檢測
The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for more than 60 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test CAN help inform clinicians about how a patient's genes may impact how they metabolize and/or respond to certain psychiatric medications. Tens of thousands of clinicians have ordered the GeneSight test for almost three million patients in order to receive genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. The clinical validity, clinical utility and economic utility of the GeneSight test have been evaluated in multiple peer-reviewed publications. Learn more at
GeneSight.com
.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit
.
關於Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights CAN signifiCANtly improve patient care and lower healthcare costs. For more information, visit
.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's plan to continue its dialogue with UNH and other key stakeholders and the company's confidence in the clinical validity and utility of GeneSight, which the company believes is supported by clinical evidence, including peer-reviewed research studies. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
安全港聲明
本新聞稿包含1995年《私人證券訴訟改革法案》意義上的「前瞻性聲明」，包括有關公司計劃與UNH及其他關鍵利益相關者持續對話的聲明，以及公司對GeneSight臨牀有效性和實用性的信心，公司認爲該信心得到了臨牀證據的支持，包括經過同行評審的研究。這些「前瞻性聲明」是管理層在本日期望的未來事件，可能面臨已知和未知的風險和不確定性，這些風險和不確定性可能導致實際結果、情況和事件與預期大相徑庭，甚至不利。這些因素包括公司向美國證券交易委員會提交的文件中描述的風險，包括於2024年2月28日提交的10-K表年度報告，以及公司不時在10-Q表季度報告或8-K表當前報告中提交的風險因素更新。萬基遺傳沒有任何義務，且明確聲明沒有義務更新或更改任何前瞻性聲明，無論是由於新信息、未來事件或其他原因，除非法律要求。
1
Majtabai R, et al. J Clin Psychiatry. 2008 Jul;69(7):106574.
1
Majtabai R等。《臨牀精神病學雜誌》，2008年7月；69（7）：106574。
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
投資者聯繫
馬特·斯卡洛
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
媒體聯繫
格倫·法雷爾
(385) 318-3718
PR@myriad.com
